The latest price target for Cellectar Biosciences (NASDAQ:CLRB) was reported by Oppenheimer on December 11, 2024. The analyst firm set a price target for $0.00 expecting CLRB to fall to within 12 months (a possible -100.00% downside). 6 analyst firms have reported ratings in the last year.

The latest analyst rating for Cellectar Biosciences (NASDAQ:CLRB) was provided by Oppenheimer, and Cellectar Biosciences downgraded their perform rating.

There is no last upgrade for Cellectar Biosciences

The last downgrade for Cellectar Biosciences Inc happened on December 11, 2024 when Oppenheimer changed their price target from N/A to N/A for Cellectar Biosciences Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cellectar Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cellectar Biosciences was filed on December 11, 2024 so you should expect the next rating to be made available sometime around December 11, 2025.

While ratings are subjective and will change, the latest Cellectar Biosciences (CLRB) rating was a downgraded with a price target of $0.00 to $0.00. The current price Cellectar Biosciences (CLRB) is trading at is $0.30, which is out of the analyst’s predicted range.